Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McDonald's Corp (MCD) vs Viatris Inc (VTRS) Price & Performance

McDonald's CorpTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

McDonald's Corp vs Viatris Inc — how do they compare? McDonald's Corp trades at $273.96 (market cap $193.70B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: McDonald's Corp is far larger — about 10.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.

MCDVTRS
Market Cap
$193.70B$18.69B
Volume
2,230,036
Sector
Consumer CyclicalHealth
52-Week High
$341.06$17.86
52-Week Low
$262.80$9.49
Enterprise Value
$247.47B$30.81B
Dividend Yield
2.72%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McDonald's Corp

McDonald's (MCD) trades at $274.15, down slightly by 0.12% on the day, with technical indicators showing a neutral overall signal. The company demonstrates strong fundamentals with consistent revenue growth, reaching $26.89 billion in 2025, and robust profitability with a 31.72% net income margin. Recent earnings have consistently beaten expectations, and the company has announced a new global growth strategy focused on automation and menu innovation to drive future performance.

The outlook for MCD is positive, supported by strong analyst consensus with a $322.45 price target implying significant upside. Key opportunities include the successful execution of its new growth plan and its defensive qualities in a challenging economy. Primary risks involve inflationary pressures on franchisee margins and intense competition in the quick-service restaurant sector.

Viatris Inc

Viatris (VTRS) trades at $16.43, up 0.86% with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, with revenues rising 5% year-over-year. However, fundamental challenges persist with negative net income margin (-2.79%) and elevated P/E ratio (236.2). Recent developments include FDA approval for Gwyn Lo contraceptive patch and strategic divestitures to sharpen focus.

While Viatris shows operational improvements with consistent cash flow generation, the stock faces headwinds from profitability challenges and high valuation multiples. The mixed analyst sentiment (30.77% buy rating) reflects uncertainty about the company's turnaround trajectory. Key risks include ongoing margin pressure and competitive threats in the generic pharmaceutical space.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About McDonald's Corp

McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.

Read more on MCD

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS